Panel Discussion: What Have we Learned from the Last 12 Months of Alzheimer’s Drug Development?
Time: 8:15 am
day: Conference Day One AM
Details:
- What have been the main obstacles to integrating first class of anti-amyloids into the treatment paradigm?
- What is the impact of ARIA on penetration of these new anti-amyloid therapies into market? What is the plan to better manage the burden of ARIA going forward?
- Shifting focus to new emerging therapies: From anti-inflammatory and anti-tau treatments to combination therapies, what are the most promising novel approaches in the pipeline?
